Schmidt JE, et al. Prevalence of perceived cognitive dysfunction in survivors of a wide range of cancers: results from the 2010 LIVESTRONG survey. J Cancer Surviv. 2016;10(2):302–11.

Article  PubMed  Google Scholar 

Mayo SJ, et al. Cancer-related cognitive impairment in patients with non-central nervous system malignancies: an overview for oncology providers from the MASCC neurological complications study group. Support Care Cancer. 2021;29(6):2821–40.

PubMed  Google Scholar 

Phillips NS, et al. Neurotoxic effects of childhood cancer therapy and its potential neurocognitive impact. J Clin Oncol. 2021;39(16):1752–65.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Ahles TA, Root JC. Cognitive effects of cancer and cancer treatments. Annu Rev Clin Psychol. 2018;14:425–51.

Article  PubMed  PubMed Central  Google Scholar 

Prasad PK, et al. Psychosocial and neurocognitive outcomes in adult survivors of adolescent and early young adult cancer: a report from the childhood cancer survivor study. J Clin Oncol. 2015;33(23):2545–52.

Article  PubMed  PubMed Central  Google Scholar 

Kunin-Batson A, et al. Predictors of independent living status in adult survivors of childhood cancer: a report from the Childhood Cancer Survivor Study. Pediatr Blood Cancer. 2011;57(7):1197–203.

Article  PubMed  PubMed Central  Google Scholar 

Vizer LM, Mikles SP, Piepmeier AT. Cancer-related cognitive impairment in survivors of adolescent and young adult non-central nervous system cancer: a scoping review. Psychooncology. 2022;31(8):1275–85.

Article  PubMed  Google Scholar 

Olson B, Marks DL. Pretreatment cancer-related cognitive impairment-mechanisms and outlook. Cancers (Basel). 2019. https://doi.org/10.3390/cancers11050687.

Article  PubMed  PubMed Central  Google Scholar 

Shamsesfandabadi P, et al. Radiation-induced cognitive decline: challenges and solutions. Cancer Manag Res. 2024;16:1043–52.

Article  PubMed  PubMed Central  Google Scholar 

Soffietti R, et al. Neurotoxicity from old and new radiation treatments for brain tumors. Int J Mol Sci. 2023. https://doi.org/10.3390/ijms241310669.

Article  PubMed  PubMed Central  Google Scholar 

Mounier NM, et al. Chemotherapy-induced cognitive impairment (CICI): An overview of etiology and pathogenesis. Life Sci. 2020;258:118071.

Article  CAS  PubMed  Google Scholar 

Murillo LC, Sutachan JJ, Albarracin SL. An update on neurobiological mechanisms involved in the development of chemotherapy-induced cognitive impairment (CICI). Toxicol Rep. 2023;10:544–53.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Deprez S, et al. Longitudinal assessment of chemotherapy-induced structural changes in cerebral white matter and its correlation with impaired cognitive functioning. J Clin Oncol. 2012;30(3):274–81.

Article  PubMed  Google Scholar 

Kesler SR, et al. Brain imaging in pediatric cancer survivors: correlates of cognitive impairment. J Clin Oncol. 2021;39(16):1775–85.

Article  PubMed  PubMed Central  Google Scholar 

Boue A, et al. Does hormone therapy impact cognition in patients with prostate cancer? A systematic review and meta-analysis. Cancer. 2024;130(12):2120–38.

Article  PubMed  Google Scholar 

Wu LM, Amidi A. Cognitive impairment following hormone therapy: current opinion of research in breast and prostate cancer patients. Curr Opin Support Palliat Care. 2017;11(1):38–45.

Article  PubMed  PubMed Central  Google Scholar 

Schagen SB, et al. Cognitive adverse effects of chemotherapy and immunotherapy: are interventions within reach? Nat Rev Neurol. 2022;18(3):173–85.

Article  PubMed  Google Scholar 

Cancer Moonshot℠ - Recent Fiscal Year Funding. Available from: https://www.cancer.gov/about-nci/budget/fact-book/cancer-moonshot.

Institute, N.C. Highlighted Scientific Opportunities in Cancer Research. 2024 September 4, 2024 [cited 2025 February 25]; Available from: https://www.cancer.gov/research/leading-progress/scientific-opportunities.

NIH. Grants & Funding. Available from: https://www.nih.gov/grants-funding.

Doose M, et al. Advancing health equity in cancer survivorship research: National Institutes of Health 2017–2022 portfolio review. J Natl Cancer Inst. 2024;116(8):1238–45.

Article  PubMed  PubMed Central  Google Scholar 

Mollica MA, et al. Current state of funded National Institutes of Health grants focused on individuals living with advanced and metastatic cancers: a portfolio analysis. J Cancer Surviv. 2021;15(3):370–4.

Article  PubMed  Google Scholar 

Altshuler RD, et al. Chemotherapy-induced peripheral neuropathy research: a National Institutes of Health (NIH) grant portfolio analysis (2014–2023). JNCI Cancer Spectr. 2025. https://doi.org/10.1093/jncics/pkaf039.

Article  PubMed  PubMed Central  Google Scholar 

NIH. Activity Codes. 2025 March 4 [cited 2025 March 4]; Available from: https://grants.nih.gov/funding/activity-codes.

SEER*Rx. Surveillance Research Program (SRP) in NCI's Division of Cancer Control and Population Sciences (DCCPS). [cited 2025 May 15]; Available from: https://seer.cancer.gov/tools/seerrx/.

Strehle LD, et al. Microglia contribute to mammary tumor-induced neuroinflammation in a female mouse model. FASEB J. 2024;38(2):e23419.

Article  CAS  PubMed  Google Scholar 

Duong SL, et al. Neurotoxicities associated with immune checkpoint inhibitor therapy. J Neurooncol. 2021;152(2):265–77.

Article  CAS  PubMed  Google Scholar 

Dubey D, et al. Severe neurological toxicity of immune checkpoint inhibitors: growing spectrum. Ann Neurol. 2020;87(5):659–69.

Article  PubMed  Google Scholar 

Fleming B, Edison P, Kenny L. Cognitive impairment after cancer treatment: mechanisms, clinical characterization, and management. BMJ. 2023;380:e071726.

Article  CAS  PubMed  Google Scholar 

Briggs LG, et al. Neurocognitive impairment associated with traditional and novel androgen receptor signaling inhibitors +/- androgen deprivation therapy: a pharmacovigilance study. Prostate Cancer Prostatic Dis. 2023;26(2):331–7.

Article  CAS  PubMed  Google Scholar 

Winocur G, Johnston I, Castel H. Chemotherapy and cognition: International cognition and cancer task force recommendations for harmonising preclinical research. Cancer Treat Rev. 2018;69:72–83.

Article  PubMed  Google Scholar 

SEER. Cancer Stat Facts: Common Cancer Sites. 2024 [cited 2025 Feb 25]; Available from: https://seer.cancer.gov/statfacts/html/common.html.

Sung H, et al. Colorectal cancer incidence trends in younger versus older adults: an analysis of population-based cancer registry data. Lancet Oncol. 2025;26(1):51–63.

Article  PubMed  PubMed Central  Google Scholar 

Wefel JS, et al. International cognition and cancer task force recommendations to harmonise studies of cognitive function in patients with cancer. Lancet Oncol. 2011;12(7):703–8.

Article  PubMed  Google Scholar 

Adedinsewo D, et al. Health disparities, clinical trials, and the digital divide. Mayo Clin Proc. 2023;98(12):1875–87.

Article  PubMed  Google Scholar 

Scott EC, et al. Trends in the approval of cancer therapies by the FDA in the twenty-first century. Nat Rev Drug Discov. 2023;22(8):625–40.

Article  CAS  PubMed  Google Scholar 

Burton LB, et al. A review of neurotoxicities associated with immunotherapy and a framework for evaluation. Neurooncol Adv. 2021;3(Suppl 5):v108–20.

PubMed  PubMed Central  Google Scholar 

Janelsins MC, et al. The national cancer institute clinical trials planning meeting to address gaps in observational and intervention trials for cancer-related cognitive impairment. JNCI J Natl Cancer Inst. 2024.